Brief: Nkgen Biotech Selected As Preferred Stalking Horse Bidder For Nkmax Co.
02/12/2024 21:16
Dec 2 (Reuters) - Nkgen Biotech Inc NKGN.O :
* NKGEN BIOTECH: SELECTED AS PREFERRED STALKING HORSE BIDDER
FOR
NKMAX CO., IN NKMAX'S COURT-MANAGED REHABILITATION PROCESS IN
SOUTH KOREA
Source text: ID:nGNX8Cv8dl
Further company coverage: NKGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program